S&P 500   3,365.17 (-0.24%)
DOW   27,773.61 (-0.44%)
AAPL   455.84 (-0.91%)
CGC   17.20 (-0.69%)
BABA   256.20 (+0.98%)
TSLA   1,649.07 (+1.73%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
S&P 500   3,365.17 (-0.24%)
DOW   27,773.61 (-0.44%)
AAPL   455.84 (-0.91%)
CGC   17.20 (-0.69%)
BABA   256.20 (+0.98%)
TSLA   1,649.07 (+1.73%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
S&P 500   3,365.17 (-0.24%)
DOW   27,773.61 (-0.44%)
AAPL   455.84 (-0.91%)
CGC   17.20 (-0.69%)
BABA   256.20 (+0.98%)
TSLA   1,649.07 (+1.73%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
S&P 500   3,365.17 (-0.24%)
DOW   27,773.61 (-0.44%)
AAPL   455.84 (-0.91%)
CGC   17.20 (-0.69%)
BABA   256.20 (+0.98%)
TSLA   1,649.07 (+1.73%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
Log in

LON:SCLPScancell Share Price, Forecast & News

GBX 7.25
+0.25 (+3.57 %)
(As of 08/14/2020 09:34 AM ET)
Add
Compare
Today's Range
6.75
Now: GBX 7.25▼
7.80
50-Day Range
5.25
MA: GBX 6.12▼
7
52-Week Range
0.05
Now: GBX 7.25▼
9.93
Volume3.82 million shs
Average Volume536,966 shs
Market Capitalization£34.15 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Scancell Holdings plc engages in the discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer in the United Kingdom. The company's products include SCIB1, a plasmid DNA vaccine, which is in Phase I/II clinical trials for the treatment of melanoma; SCIB2 to treat lung cancer antigen; and Modi-1, which is in the pre-clinical development to treat triple negative breast cancer, ovarian cancer, and sarcoma. It is also developing Modi-2, a moditope program that is in pre-clinical development to address multiple cancer indications. Scancell Holdings plc has a research collaboration agreement with BioNTech to develop T-cell therapies for the treatment of cancer. It also has a licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the manufacturing, development, and commercialization of Modi-1. The company was incorporated in 2008 and is based in Oxford, the United Kingdom.
Read More
Scancell logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.60 out of 5 stars


Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:SCLP
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.scancell.co.uk
Phone+44-115-8231863

Debt

Debt-to-Equity RatioN/A
Current Ratio10.23
Quick Ratio10.23

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowGBX 1.29 per share
Price / Cash Flow5.63
Book ValueGBX 2.30 per share
Price / Book3.15

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees19
Outstanding Shares471,065,984
Market Cap£34.15 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 7.25
+0.25 (+3.57 %)
(As of 08/14/2020 09:34 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SCLP News and Ratings via Email

Sign-up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Scancell (LON:SCLP) Frequently Asked Questions

How has Scancell's stock price been impacted by Coronavirus?

Scancell's stock was trading at GBX 5.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SCLP shares have increased by 23.9% and is now trading at GBX 7.25.
View which stocks have been most impacted by COVID-19.

How were Scancell's earnings last quarter?

Scancell Holdings Plc (LON:SCLP) issued its quarterly earnings data on Friday, January, 31st. The company reported ($0.56) EPS for the quarter.
View Scancell's earnings history.

Has Scancell been receiving favorable news coverage?

Media stories about SCLP stock have been trending positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Scancell earned a news impact score of 2.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Scancell.

Who are some of Scancell's key competitors?

Some companies that are related to Scancell include Lineage Cell Therapeutics (LCTX), Imugene (IMU), Verseon (VSN), Orgenesis (ORGS), MediGene (MDG1), Senesco Technologies (ELOX), Immunoprecise Antibodies (IPA), Orgenesis (ORGS), Circassia Pharmaceuticals (CIR), Protalix Biotherapeutics (PLX), Ampliphi Biosciences (APHB), CorMedix (CRMD), Antibe Therapeutics (ATE), CorMedix (CRMD) and OncoCyte (OCX).
View all competitors.

What other stocks do shareholders of Scancell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scancell investors own include KAZ Minerals (KAZ), Standard Chartered (STAN), Petropavlovsk (POG), Ascential (ASCL), AorTech International (AOR), Advanced Oncotherapy (AVO), Empyrean Energy (EME), Lloyds Banking Group (LYG), Aminex (AEX) and Sound Energy (SOU).

Who are Scancell's key executives?

Scancell's management team includes the following people:
  • Dr. John Chiplin BPharm, MRPharmS, Ph.D., Exec. Chairman (Age 60)
  • Dr. Clifford Holloway, Chief Exec. Officer
  • Prof. Lindy Gillian Durrant Ph.D., Chief Scientific Officer & Director
  • Dr. Sally Elizabeth Adams, Devel. Director & Director (Age 58)
  • Mr. Keith Green, Director of Fin. & Admin.

What is Scancell's stock symbol?

Scancell trades on the London Stock Exchange (LON) under the ticker symbol "SCLP."

How do I buy shares of Scancell?

Shares of SCLP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Scancell's stock price today?

One share of SCLP stock can currently be purchased for approximately GBX 7.25.

How big of a company is Scancell?

Scancell has a market capitalization of £34.15 million. Scancell employs 19 workers across the globe.

What is Scancell's official website?

The official website for Scancell is www.scancell.co.uk.

How can I contact Scancell?

Scancell's mailing address is Department of Clinical Oncology Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231863.

This page was last updated on 8/14/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.